Skip to main content
TipRanks
Go Ultimate75% OFF

Canopy Growth (11L) Q2 2027 Earnings Report

31 Followers

DE:11L Q2 2027 EPS Results

Actual EPS
-EUR 0.06
Consensus EPS
-EUR 0.02
Beat/Miss
Missed by -EUR 0.04
One Year Ago EPS
-EUR 0.01

DE:11L Q2 2027 Revenue Results

Actual Revenue
EUR 51.60M
Expected Revenue
EUR 52.12M
Beat/Miss
Missed by -EUR 517.48K
YoY Revenue Growth
+22.03%

Earnings Announcement Details

Quarter
Q2 2027
Date
11/06/2026
Time
Before Open
Conference Call
Friday, November 6, 2026
DE:11L Upcoming Earnings

Canopy Growth's next earnings date is estimated for February 5, 2027, based on past reporting schedules.

Q2 2027 Earnings Call Audio

DE:11L Q2 2027 Earnings Call
0:00 / 0:00

Q2 2027 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2027 Earnings Call Summary

Q2 2027
Earnings Call Date:Nov 06, 2026|% Change Since:-28.88%|
Earnings Call Sentiment|Positive

The call was predominantly positive. Canopy reported strong consolidated, cannabis, international, medical, and adult-use revenue growth; improved operating efficiency; a narrower adjusted EBITDA loss; substantial liquidity; and progress in cultivation, EU GMP certification, and international expansion. The main negative factors were the 44% decline in Storz & Bickel revenue, lower consolidated gross margin due primarily to the Veteran Affairs Canada reimbursement-rate reduction, ongoing negative adjusted EBITDA, and the company's acknowledgment that cultivation costs are not yet best in class. Management nevertheless expressed confidence in achieving positive adjusted EBITDA in the second half of fiscal 2027 and in realizing further benefits from cultivation and operating initiatives.

Company Guidance

Canopy expects to deliver positive adjusted EBITDA in the second half of this fiscal year, with a stronger back half supported partly by seasonality in Storz & Bickel, which is expected to have a seasonally strong quarter in Q3 driven by the holiday season. The company expects a noticeable increase in yield and flower quality as it exits the third quarter of fiscal 27, with the full impact being felt in the start of fiscal 28, and believes there is the potential to increase flower production at Kincardine by at least 25% to 30% within the same physical footprint. Canopy remains on track to reach a target run rate of $10 million of annualized synergies within 18 months of the March 2026 closing of the MTL transaction; cultivation enhancements are expected to benefit the P&L as the company is exiting FY 2027, while manufacturing and distribution initiatives implemented in the back half of fiscal 27 are expected to provide full benefits in fiscal 28.

  • Consolidated Revenue GrowthConsolidated net revenue increased 22% year over year to $81.4 million in the second quarter of fiscal 2027, driven by broad-based momentum across the business.
  • Cannabis Segment GrowthCannabis revenue increased 30% year over year to $66.2 million, reflecting the company's ability to produce and supply high-quality flower to meet demand in Canadian and European markets.
  • International Cannabis SurgeInternational cannabis net revenue increased 141% year over year and 28% sequentially to $12.3 million, enabled by strong flower availability and a strengthened route-to-market that expanded access to patients in core European markets.
  • Canada Medical Revenue GrowthCanada Medical net revenue grew 18% year over year to $25.8 million, benefiting from ongoing patient-count increases, including the addition of the MTL Medical business.
  • Canada Adult-Use MomentumCanada Adult Use net revenue increased 17% year over year to $21.8 million, supported by a strengthened product portfolio and the addition of MTL brands, which performed well in Quebec and were building momentum across the rest of Canada.
  • Cultivation Yield Improvement ProgramCanopy is applying MTL's master-grower expertise and new cultivation methods at its EU GMP facility in Kincardine. Early results were described as encouraging, with the company expecting a noticeable increase in yield and flower quality as it exits the third quarter of fiscal 2027 and the full impact beginning in fiscal 2028. Management believes flower production could increase by at least 25% to 30% within the same physical footprint.
  • Expanded EU GMP Supply ChainCanopy received EU GMP certification at its Smiths Falls facility and renewed EU GMP certification at Kincardine, making it the only Canadian company with end-to-end EU GMP certification covering cultivation through manufacturing and primary packaging of sublingual oils and dry cannabis flower.
  • European Product and Market ExpansionThe Smiths Falls certification creates a path to expand beyond flower into additional patient-ready product categories in Europe. Canopy also relaunched Tweed in Germany with MTL Cannabis Genetics, strengthened its German commercial and operational leadership, broadened its product offering in Australia, and entered the U.K. medical cannabis market.
  • Germany and Poland Brand PositioningManagement said Canopy's brands and genetics resonate with patients, doctors, pharmacists, and industry participants in Germany and Poland. The company stated that it performed well whenever it had product in stock and is strengthening its European sales team and patient access.
  • Operating Efficiency and SynergiesSG&A expense in the second quarter was approximately $5 million lower sequentially than in the first quarter. Despite absorbing the full MTL business, which typically incurred approximately $6 million of SG&A expense, SG&A increased only $3.4 million year over year. Canopy remains on track to achieve $10 million of annualized synergies within 18 months of the March 2026 MTL closing.
  • Improving Adjusted EBITDAAdjusted EBITDA loss was $2.9 million in the second quarter of fiscal 2027, an improvement of $400,000 from the first quarter. Management remains on track to deliver positive adjusted EBITDA in the second half of fiscal 2027.
  • Storz & Bickel Margin Improvement and InnovationDespite lower revenue, Storz & Bickel gross margin increased from 38% in the second quarter of the prior year to 39% this year due to cost efficiencies under the new management team. First-half fiscal 2027 margins were well above the 33% reported for the full fiscal 2026 year. The Venti received the Safe Access Now Flower Vaporization Innovation Award, and management expects a seasonally strong third quarter driven by the holiday season.
  • Strong Liquidity and Capital FlexibilityCanopy had $320 million of cash and short-term investments as of September 30, 2026. The company has not sold shares through its ATM program since December 2025 and said it would use the program selectively for strategic opportunities, including M&A where it sees a compelling path to shareholder value creation.
  • Improved Free Cash Outflow Despite Higher Capital InvestmentFree cash outflow improved by $3.7 million year over year to $15.6 million in the second quarter, despite an $1.8 million increase in capital expenditures to invest in the cultivation facility.
  • Additional Manufacturing and Distribution InitiativesCanopy began streamlining its manufacturing and distribution efforts around the Smiths Falls facility. Initiatives are planned for the second half of fiscal 2027, with benefits expected to begin later in the fiscal year and full benefits in fiscal 2028.
  • Potentially Supportive Canadian Policy ChangesManagement described proposed Canadian government budget changes relating to cannabis as very encouraging, saying they could make it commercially easier for Canadian licensed producers to operate and provide Canadians with greater access to quality flower grown and distributed through the regulated system.

DE:11L Earnings History

DE:11L earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 05, 20272027 (Q3)-0.03--0.11――
Nov 06, 20262027 (Q2)-0.02-0.06-0.01-900.00% (-0.06)
Aug 07, 20262027 (Q1)-0.04-0.02-0.1486.36% (+0.12)
Jun 15, 20262026 (Q4)-0.06-0.25-0.9172.03% (+0.65)
Feb 06, 20262026 (Q3)-0.04-0.11-0.783.78% (+0.59)
Nov 07, 20252026 (Q2)-0.10-0.01-0.9499.32% (+0.93)
Aug 08, 20252026 (Q1)-0.15-0.14-1.0186.25% (+0.88)
May 30, 20252025 (Q4)-0.29-0.91-0.65-38.83% (-0.25)
Feb 07, 20252025 (Q3)-0.30-0.70-1.6657.63% (+0.96)
Nov 08, 20242025 (Q2)-0.29-0.94-2.7365.58% (+1.79)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed